First Tracks Biotherapeutics, Inc.
Key Metrics
Market Snapshot
About
First Tracks Biotherapeutics, Inc. (TRAX) is a clinical-stage biotechnology company based in San Diego, California, that focuses on developing immunology therapeutics for autoimmune and inflammatory diseases in the United States. Founded in 2019, the company is best known for a pipeline of antibody-based treatments aimed at conditions driven by the immune system. It was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026.
The company's pipeline centers on several product candidates that target specific parts of the immune response. ANB033 is an anti-CD122 antagonist that acts on the shared beta subunit of the IL-15 and IL-2 receptors. Rosnilimab is an antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues. ANB101 is a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells, a cell type involved in inflammatory and autoimmune processes.
As a clinical-stage company, First Tracks Biotherapeutics is focused on advancing these candidates through development rather than selling approved products, so it does not yet earn revenue from marketed therapies. Its work concentrates on autoimmune and inflammatory diseases, where the immune system mistakenly attacks the body or drives harmful inflammation, and its candidates reflect different approaches to dialing down that activity. The company's prospects are tied to the progress of ANB033, rosnilimab, and ANB101 through clinical testing. Having recently adopted its new name in 2026, TRAX continues to develop its immunology portfolio from its base in San Diego, with its future shaped by the outcomes of these programs.